Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Despite clinical benefits of sodium glucose co-transporter-2 inhibitors (SGLT2i), recommended by current guidelines for the treatment of chronic kidney disease (CKD), there is still an unmet need for managing residual risk of disease progression. Balcinrenone is a novel, non-steroidal mineralocorticoid receptor antagonist (MRA) expected to maintain the cardio-renal benefits of MR antagonists with a reduced risk of hyperkalaemia based on pre-clinical data. Balcinrenone in combination with dapagliflozin may provide complementary and additive kidney and cardiovascular protection. The Phase 2 MIRO-CKD study tested the hypothesis that the combination of balcinrenone with dapagliflozin is superior to dapagliflozin alone in reducing albuminuria in patients with CKD and characterized the safety and tolerability of the combination.
MIRO-CKD is a phase 2b, global, randomized, double-blind, parallel-group trial in adults with CKD and eGFR ≥ 25 to < 60 mL/min/1.73 m2, albuminuria in terms of UACR > 100 to ≤ 5000 mg/g and a serum potassium within normal range (NCT06350123). Participants were randomised 1:1:1 to oral balcinrenone/dapagliflozin 15 mg/10 mg, balcinrenone/dapagliflozin 40 mg/10 mg or placebo/dapagliflozin 10 mg for 12 weeks.
MIRO-CKD has recently been completed, and the primary results will be released later this year. Between May and December 2024, 324 participants were randomized across 15 countries in Asia, Europe, North and South America. At study entry, 58% of participants had CKD stage 3b-4 and 56% had type 2 diabetes, both important risk factors for CKD disease progression. Moreover, 86% of participants were using angiotensin converting enzyme inhibitors or angiotensin receptor blockers, which together with a mean serum potassium of 4.5 mmol/L at baseline, and ≥ 4.8 mmol/L in 30% of participants, is indicative of a study population at increased risk of serum potassium elevation and hyperkalaemia events.
A prespecified secondary analysis will investigate effects from balcinrenone/dapagliflozin compared to placebo/dapagliflozin on serum potassium levels and risk of hyperkalaemia, including effects across subgroups defined by eg eGFR and potassium levels at baseline, and diabetes status. Correlation analyses will explore potential associations between changes in potassium levels during balcinrenone/dapagliflozin treatment in the context of concomitant changes in such as albuminuria, eGFR, and blood pressure. The results will be submitted for presentation at the WCN Annual meeting 2026.
The secondary analyses of effects on serum potassium and hyperkalaemia to be presented at the WCN Annual meeting will provide further understanding of the safety and tolerability of the novel combination of balcinrenone and dapagliflozin in a contemporary CKD population at increased risk of disease progression and with an increased risk of hyperkalaemia.
